Interventionelle renale Sympathikusdenervation zur Behandlung der therapieresistenten Hypertonie Expert consensus statement on interventional renal sympathetic denervation for hypertension treatment

This commentary summarizes the expert consensus and recommendations of the working group 'Herz und Niere' of the German Society of Cardiology (DGK), the German Society of Nephrology (DGfN) and the German Hypertension League (DHL) on renal denervation for antihypertensive treatment. Renal denervation is a new, interventional approach to selectively denervate renal afferent and efferent sympathetic fibers. Renal denervation has been demonstrated to reduce office systolic and diastolic blood pressure in patients with resistant hypertension, defined as systolic office blood pressure ≥ 160 mm Hg and ≥ 150 mm Hg in patients with diabetes type 2, which should currently be used as blood pressure thresholds for undergoing the procedure. Exclusion of secondary hypertension causes and optimized antihypertensive drug treatment is mandatory in every patient with resistant hypertension. In order to exclude pseudoresistance, 24-hour blood pressure measurements should be performed. Preserved renal function was an inclusion criterion in the Symplicity studies, therefore, renal denervation should be only considered in patients with a glomerular filtration rate > 45 ml/min. Adequate centre qualification in both, treatment of hypertension and interventional expertise are essential to ensure correct patient selection and procedural safety. Long-term follow-up after renal denervation and participation in the German Renal Denervation (GREAT) Registry are recommended to assess safety and efficacy after renal denervation over time.

[1]  H. Krum,et al.  Cardiorespiratory response to exercise after renal sympathetic denervation in patients with resistant hypertension. , 2011, Journal of the American College of Cardiology.

[2]  D. Calhoun,et al.  Aldosterone Blockers (Mineralocorticoid Receptor Antagonism) and Potassium‐Sparing Diuretics , 2011, Journal of clinical hypertension.

[3]  H. Krum,et al.  Effect of Renal Sympathetic Denervation on Glucose Metabolism in Patients With Resistant Hypertension: A Pilot Study , 2011, Circulation.

[4]  L. Rump,et al.  [Medical vs. interventional therapy of renal artery stenosis: ASTRAL study (Angioplasty and STenting for Renal Artery Lesions)]. , 2011, Der Internist.

[5]  H. Krum,et al.  Device-Based Antihypertensive Therapy: Therapeutic Modulation of the Autonomic Nervous System , 2011, Circulation.

[6]  H. Krum,et al.  Renal sympathetic denervation in patients with treatment-resistant hypertension (The Symplicity HTN-2 Trial): a randomised controlled trial , 2010, The Lancet.

[7]  M. Böhm,et al.  Interventionelle renale Sympathikusdenervation , 2010, Deutsche medizinische Wochenschrift.

[8]  B. Epstein.  Improving blood pressure control rates by optimizing combination antihypertensive therapy , 2010, Expert opinion on pharmacotherapy.

[9]  R. Düsing.  Optimizing blood pressure control through the use of fixed combinations , 2010, Vascular health and risk management.

[10]  O. Vonend,et al.  Aldosteron und Hypertonie , 2010, Wiener klinische Wochenschrift.

[11]  F. Scolari,et al.  Atheroembolic renal disease , 2009, The Lancet.

[12]  M. Böhm,et al.  Neue Methode , 2009 .

[13]  S. Douma,et al.  Interventional management of resistant hypertension , 2009, The Lancet.

[14]  Krzysztof Bartus,et al.  Catheter-based renal sympathetic denervation for resistant hypertension: a multicentre safety and proof-of-principle cohort study , 2009, The Lancet.

[15]  I. Quack,et al.  Niere und Hypertonie , 2009, Der Internist.

[16]  W. Young,et al.  Case detection, diagnosis, and treatment of patients with primary aldosteronism: an endocrine society clinical practice guideline. , 2008, The Journal of clinical endocrinology and metabolism.

[17]  E. Ritz,et al.  NON‐CORONARY HEART DISEASE IN DIALYSIS PATIENTS: Sympathetic Overactivity—The Cinderella of Cardiovascular Risk Factors in Dialysis Patients , 2008, Seminars in dialysis.

[18]  D. Goff,et al.  Resistant hypertension: diagnosis, evaluation, and treatment: a scientific statement from the American Heart Association Professional Education Committee of the Council for High Blood Pressure Research. , 2008, Circulation.

[19]  A. Voiculescu,et al.  Hypertonie bei Patienten mit Nierenarterienstenosen , 2008, Der Internist.

[20]  B. Sanner,et al.  Continuous positive airway pressure treatment of mild to moderate obstructive sleep apnea reduces cardiovascular risk. , 2007, American journal of respiratory and critical care medicine.

[21]  A. Colombo,et al.  Renal Insufficiency Following Contrast Media Administration Trial (REMEDIAL): A Randomized Comparison of 3 Preventive Strategies , 2007, Circulation.

[22]  H. Völzke,et al.  Epidemiologie der arteriellen Hypertonie in Deutschland , 2006 .

[23]  G. Dibona.  Physiology in perspective: The Wisdom of the Body. Neural control of the kidney. , 2005, American journal of physiology. Regulatory, integrative and comparative physiology.

[24]  R. Cooper,et al.  Hypertension Treatment and Control in Five European Countries, Canada, and the United States , 2004, Hypertension.

[25]  E. Ritz,et al.  Sympathetic overactivity in renal disease: a window to understand progression and cardiovascular complications of uraemia? , 2000, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

[26]  L. Rump,et al.  α‐Adrenergic regulation of human renal function , 1996 .